mobile menu toggle

What we do here
changes lives everywhere.

Follow the science:

Identifying BCL-2 as a protein cancer cells use to prevent self-destruction leads to the BCL-2 inhibitor venetoclax, which has become a powerful agent in the fight against CLL and AML.

Identifying the EGFR mutation leads to the first broad application of precision medicine in lung cancer – which is paving the way for other active targeted lung cancer therapies.

Combining treatments of the PD-L1 and CTLA-4 pathways creates a “double assault” that is effective for melanoma, kidney and other cancers.

Understanding how cancer hijacks the body’s oxygen-sensing system leads to new therapies for kidney cancer, heart disease and more.

Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.

One advanced cancer discovery after another for 75 years.

Next-Generation Drug Improves Progression-Free Survival in Relapsed Chronic Lymphocytic Leukemia

A head-to-head clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has found that zanubrutinib, a next-generation BTK inhibitor, was more effective at preventing disease progression and better tolerated than ibrutinib, the...

Learn more >

Dana-Farber research supports FDA approval of new therapy for certain patients with ovarian cancer

A novel antibody drug conjugate therapy whose clinical trial testing has been co-led by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November 14 for the treatment of recurrent platinum-resistant...

Learn more >

Symposium highlights 75 years of Dana-Farber science

Seventy-five years of research that has recast the understanding, treatment, and prevention of cancer took center stage at the Dana-Farber 2022 Scientific Symposium on Sept. 29. The all-day event featured nearly 20 presentations on topics such as the evolution of basic research at the Institute, the...

Learn more >

Three-drug combination slows progression of advanced kidney cancer

Patients treated with the three-drug combination had a 27% lower risk of progression or death compared to those on the two immunotherapy drugs. COSMIC-313 trial is the first phase 3 trial in metastatic renal cell carcinoma to use nivolumab plus ipilimumab, a contemporary standard of care, as the...

Learn more >

Dana-Farber Cancer Institute Celebrates 75th Anniversary

Commemoration to showcase decades of progress and leadership in cancer care and research Dana-Farber Cancer Institute is launching a year-long celebration of its 75th anniversary to highlight its history and progress in cancer care and transformative cancer research. In marking the notable...

Learn more >

  • Twitter logo
  • Pinterest logo
  • Facebook logo
  • LinkedIn logo
  • YouTube logo
  • Instagram logo
Best Children's Hospitals Award from US News
Best Hospitals Award from US News
Harvard Medical School
Magnet Recognized
Dana-Farber building